Urothelial carcinoma is a complex cancer with genomic immunomic drivers that have
prognostic and predictive treatment implications. Identifying potential targetable alterations …

Discovery-driven research and clinical research have worked together to change the
outcomes of many cancer patients. We choose urothelial carcinoma as an example to …

Landmark papers published in 2017 have advanced our understanding of the molecular
heterogeneity of urothelial cancer, provided insights into the genomic evolution of the …

The clinical standard of care for urothelial carcinoma (UC) relies on invasive procedures
with suboptimal performance. To enhance UC treatment, we developed a urinary …

Bladder cancer is the fourth most common cancer in men and fifth most common overall. The
use of next-generation sequencing (NGS) approaches is crucial to precisely characterize the …

Survival of patients with urothelial carcinoma (including bladder cancer and upper tract
urothelial carcinoma) is limited by our current approaches to staging, surgery, and …

We present an evolutionary analysis of the relative time of genetic events underlying
tumorigenesis in human bladder cancers from 10 whole cystectomy specimens using …

Purpose This study aimed to explore the genomic and transcriptomic landscape of bladder
cancer (BC) and its implication for treatment with an immune checkpoint inhibitor (ICI) …

BACKGROUND In the current study, the authors present a comprehensive genomic profile
(CGP)‐based study of advanced urothelial carcinoma (UC) designed to detect clinically …

Purpose Urothelial carcinoma of the bladder (UCB) is a common malignancy with limited
systemic treatment options in advanced stages. Despite recent advances in immunotherapy …